A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry

 In Publication
0
Recent Posts
0

Start typing and press Enter to search

Dynavax — Pharmacodynamic changes confirm the mechanism of action mediating SD-101 efficacy, in combination with pembrolizumab, in a phase 1b/2 study in metastatic melanoma
Merk — Detection of PD-L1 and PD-L2 on circulating tumor cells using ChipCytometry